Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05037032 · ClinicalTrials.gov registry record · Phase 4
Effects of Naltrexone on Nocturnal Breathing Patterns at Altitude
A Phase 4 study, sponsored by VA Loma Linda Health Care System.
- Completed
- Registry status
- Phase 4
- Development phase
- 16
- Enrollment target
NCT05037032: Completed Phase 4 study, sponsored by VA Loma Linda Health Care System.
NCT05037032 is a Phase 4 study that has completed, run by VA Loma Linda Health Care System. The registered enrollment target is 16 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05037032, a Phase 4 study, has completed, sponsored by VA Loma Linda Health Care System.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 16 participants
- Enrollment target
Study Summary
Sleep at altitude is often poor. The purpose of this study is to evaluate the effects of a single dose of the opioid antagonist, naltrexone, on sleep quality and periodic breathing after rapid ascent to \~3800m altitude.
Primary Outcome
Change from baseline in nighttime SpO2
Interventions
- DRUG Placebo
- DRUG Naltrexone Pill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2021-08-08 |
| Est. Completion | 2021-10-17 |
| Phase | Phase 4 |
What the finished NCT05037032 record still lists
NCT05037032 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05037032 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05037032 about?
NCT05037032 is a clinical study titled "Effects of Naltrexone on Nocturnal Breathing Patterns at Altitude". Sleep at altitude is often poor. The purpose of this study is to evaluate the effects of a single dose of the opioid antagonist, naltrexone, on sleep quality and periodic breathing after rapid ascent to \~3800m altitude.
What is the current status of trial NCT05037032?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 16 participants. The study started on 2021-08-08. Estimated completion is 2021-10-17.
What interventions are being tested in trial NCT05037032?
The interventions under investigation include: Placebo (DRUG), Naltrexone Pill (DRUG).
Who is sponsoring clinical trial NCT05037032?
This trial is sponsored by VA Loma Linda Health Care System, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05037032's enrollment target sits among peer trials
16 1869th of 2000 higher than 121 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI